CA2098302A1 - Medicaments - Google Patents

Medicaments

Info

Publication number
CA2098302A1
CA2098302A1 CA002098302A CA2098302A CA2098302A1 CA 2098302 A1 CA2098302 A1 CA 2098302A1 CA 002098302 A CA002098302 A CA 002098302A CA 2098302 A CA2098302 A CA 2098302A CA 2098302 A1 CA2098302 A1 CA 2098302A1
Authority
CA
Canada
Prior art keywords
medicaments
solvates
indole
dimethylamino
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002098302A
Other languages
French (fr)
Other versions
CA2098302C (en
Inventor
Joanne Craig
Derek L. Crookes
Stephen J. Skittrall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Joanne Craig
Derek L. Crookes
Stephen J. Skittrall
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joanne Craig, Derek L. Crookes, Stephen J. Skittrall, Glaxo Group Limited filed Critical Joanne Craig
Publication of CA2098302A1 publication Critical patent/CA2098302A1/en
Application granted granted Critical
Publication of CA2098302C publication Critical patent/CA2098302C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Abstract

3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide sulphate salt (2:1) and pharmaceutically accept-able solvates thereof are disclosed. The compound is of use in the preparation of pharmaceutical compositions, particularly for intranasal formulations, for use in the treatment of conditions associated with cephalic pain, in particular migraine.
CA002098302A 1990-12-12 1991-12-10 Medicaments Expired - Lifetime CA2098302C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB909026998A GB9026998D0 (en) 1990-12-12 1990-12-12 Medicaments
GB9026998.6 1990-12-12
PCT/EP1991/002362 WO1992010477A1 (en) 1990-12-12 1991-12-10 Medicaments

Publications (2)

Publication Number Publication Date
CA2098302A1 true CA2098302A1 (en) 1992-06-13
CA2098302C CA2098302C (en) 2001-10-16

Family

ID=10686904

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002098302A Expired - Lifetime CA2098302C (en) 1990-12-12 1991-12-10 Medicaments

Country Status (36)

Country Link
US (2) US5554639A (en)
EP (1) EP0490689B1 (en)
JP (1) JP2994037B2 (en)
KR (1) KR100211479B1 (en)
CN (2) CN1030890C (en)
AP (1) AP230A (en)
AT (1) ATE119881T1 (en)
AU (1) AU650706B2 (en)
BE (1) BE1005085A3 (en)
CA (1) CA2098302C (en)
CH (1) CH684192A5 (en)
CY (1) CY2005A (en)
CZ (1) CZ281931B6 (en)
DE (1) DE69108200T2 (en)
DK (1) DK0490689T3 (en)
EG (1) EG20219A (en)
ES (1) ES2069836T3 (en)
FR (1) FR2670487B1 (en)
GB (2) GB9026998D0 (en)
GR (1) GR3015430T3 (en)
HK (1) HK82697A (en)
HU (1) HU211937A9 (en)
IE (1) IE62894B1 (en)
IL (1) IL100330A (en)
IS (1) IS1706B (en)
IT (1) IT1252868B (en)
MX (1) MX9102501A (en)
MY (1) MY109265A (en)
NL (1) NL9102071A (en)
NZ (1) NZ240942A (en)
PT (1) PT99757B (en)
RU (1) RU2108328C1 (en)
TW (2) TW205035B (en)
WO (1) WO1992010477A1 (en)
YU (1) YU48926B (en)
ZA (1) ZA919750B (en)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0573221T3 (en) * 1992-06-05 1998-10-07 Merck Sharp & Dohme The sulfate salt of a substituted triazole, its pharmaceutical compositions and their use in therapy
FR2749846B1 (en) * 1996-06-17 1998-09-11 Pf Medicament METHANESULFONATE SALT OF ARYLPIPERAZINE DERIVED FROM TRYPTAMINE AND ITS SOLVATES FOR PHARMACEUTICAL USE
US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6106837A (en) * 1997-05-15 2000-08-22 Hirsch; Alan R. Method of treating headaches, and article of manufacture therefor
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
US6132757A (en) * 1998-05-01 2000-10-17 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
US6187790B1 (en) 1999-03-04 2001-02-13 Neal R. Cutler Use of cilostazol for treatment of sexual dysfunction
US6426084B1 (en) * 2000-06-19 2002-07-30 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
GB9926250D0 (en) * 1999-11-06 2000-01-12 Knoll Ag Chemical process
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
US6562838B2 (en) * 2001-01-26 2003-05-13 R. T. Alamo Ventures I, L.L.C. Treatment of cardiovascular disease with quinolinone enantiomers
US6458804B1 (en) 2001-01-26 2002-10-01 R.T. Alamo Venturesi, Llc Methods for the treatment of central nervous system disorders in certain patient groups
US6451813B1 (en) 2001-01-26 2002-09-17 R. T. Alamo Ventures I, Llc Treatment of gastroparesis in certain patient groups
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
US20030096748A1 (en) * 2001-06-04 2003-05-22 The Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
US20030013753A1 (en) * 2001-06-05 2003-01-16 Ronald Aung-Din Transdermal migraine therapy
US8329734B2 (en) 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
US7041677B2 (en) * 2002-03-01 2006-05-09 R.T. Alamo Ventures I, Llc Use of monochloroflosequinan in the treatment of sexual dysfunction
US7208628B2 (en) * 2002-05-13 2007-04-24 Kansas State University Research Foundation Compositions and methods for the treatment of hepatitis C virus infection
US7074893B2 (en) * 2002-06-03 2006-07-11 Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
US20040068000A1 (en) * 2002-10-02 2004-04-08 Mintong Guo Compression coated tablets
AU2003303631B2 (en) * 2002-12-26 2008-05-29 Nuvo Pharmaceuticals (Ireland) Designated Activity Company Multilayer Dosage Forms Containing NSAIDs and Triptans
US20080213363A1 (en) * 2003-01-23 2008-09-04 Singh Nikhilesh N Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
WO2004076403A1 (en) * 2003-02-24 2004-09-10 Transform Pharmaceuticals, Inc. Sumatriptan crystalline forms, pharmaceutical compositions and methods
CA2529528A1 (en) * 2003-06-20 2004-12-29 Ronald Aung-Din Topical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
US20050089558A1 (en) * 2003-10-28 2005-04-28 Alamo Pharmaceuticals, Llc Compositions and methods for the co-formulation and administration of tramadol and propoxyphene
WO2005119607A2 (en) * 2004-06-03 2005-12-15 Tyfone, Inc. System and method for securing financial transactions
CA2569964A1 (en) * 2004-06-10 2005-12-29 Duramed Pharmaceuticals, Inc. Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
AU2006249577A1 (en) 2005-05-20 2006-11-30 Janssen Pharmaceutica N.V. Process for preparation of sulfamide derivatives
US20070166336A1 (en) * 2005-12-13 2007-07-19 David Delmarre Stable and palatable oral liquid sumatriptan compositions
AR058389A1 (en) 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv USE OF SULFAMIDE BENZO-FUSED HETEROCICLIC DERIVATIVES FOR THE TREATMENT OF OBESITY
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
AU2007253814A1 (en) 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
PL2124556T3 (en) 2006-10-09 2015-02-27 Charleston Laboratories Inc Pharmaceutical compositions
JP2010507585A (en) * 2006-10-19 2010-03-11 オースペックス・ファーマシューティカルズ・インコーポレイテッド Substituted indole
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
GB2448183A (en) * 2007-04-05 2008-10-08 Optinose As Nasal powder delivery device
EP2240022B1 (en) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
US20090252791A1 (en) * 2008-04-02 2009-10-08 Venkata Nookaraju Sreedharala Pharmaceutical compositions comprising a triptan and a nonsteroidal anti-inflammatory drug
AU2009253738B2 (en) 2008-05-27 2012-12-13 Biota Scientific Management Pty Ltd Antiviral salts
EP2306998A4 (en) * 2008-06-20 2011-06-15 Alphapharm Pty Ltd Pharmaceutical formulation
EA018567B1 (en) 2008-06-23 2013-08-30 Янссен Фармацевтика Нв Crystalline form of (2s)-(-)-n-(6-chloro-2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)sulfamide
WO2010005507A1 (en) * 2008-06-30 2010-01-14 Afgin Pharma, Llc Topical regional neuro-affective therapy
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
WO2011006012A1 (en) 2009-07-08 2011-01-13 Charleston Laboratories Inc. Pharmaceutical compositions
US9211282B2 (en) 2009-09-25 2015-12-15 Dr. Reddy's Laboratories Ltd. Formulations comprising triptan compounds
US11337962B2 (en) 2009-09-25 2022-05-24 Upsher-Smith Laboratories, Llc Formulations comprising triptan compounds
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
US20160256410A1 (en) 2015-03-02 2016-09-08 Afgin Pharma, Llc Topical regional neuro-affective therapy in mammals with cannabinoids
WO2016187013A1 (en) 2015-05-15 2016-11-24 The Regents Of The University Of Michigan Methods and compositions for the treatment of arthritis
EP3423041A4 (en) 2016-03-04 2019-09-11 Charleston Laboratories, Inc. Pharmaceutical compositions
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
AU2018366022A1 (en) 2017-11-07 2020-04-30 The Regents Of The University Of Michigan Small molecule inhibitors of shared epitope-calreticulin interactions and methods of use
US20220096438A1 (en) 2018-09-07 2022-03-31 Upsher-Smith Laboratories, Llc Methods of treating migraine
US11364225B2 (en) * 2019-08-21 2022-06-21 Bn Intellectual Properties, Inc. Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same
CN115335051A (en) * 2020-02-27 2022-11-11 拜尔哈文制药股份有限公司 Oral fast-dispersing dosage form of rimaidiazepam

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2162522B (en) * 1984-08-01 1988-02-24 Glaxo Group Ltd An indole derivative
GB8615599D0 (en) * 1986-06-26 1986-07-30 Glaxo Group Ltd Chemical compounds
GB8928208D0 (en) * 1989-12-13 1990-02-14 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
PT99757B (en) 1999-05-31
CA2098302C (en) 2001-10-16
CN1030890C (en) 1996-02-07
CN1063099A (en) 1992-07-29
GB2251614A (en) 1992-07-15
IT1252868B (en) 1995-06-28
US5705520A (en) 1998-01-06
KR100211479B1 (en) 1999-08-02
HU211937A9 (en) 1996-01-29
EP0490689B1 (en) 1995-03-15
MX9102501A (en) 1992-09-01
MY109265A (en) 1996-12-31
RU2108328C1 (en) 1998-04-10
YU48926B (en) 2002-12-10
EP0490689A1 (en) 1992-06-17
GR3015430T3 (en) 1995-06-30
IL100330A (en) 1996-06-18
IL100330A0 (en) 1992-09-06
US5554639A (en) 1996-09-10
CN1050831C (en) 2000-03-29
JPH06503560A (en) 1994-04-21
CN1128259A (en) 1996-08-07
CY2005A (en) 1997-12-05
DE69108200D1 (en) 1995-04-20
AP9100339A0 (en) 1992-01-31
GB9126297D0 (en) 1992-02-12
FR2670487A1 (en) 1992-06-19
YU191491A (en) 1994-04-05
AU650706B2 (en) 1994-06-30
TW300886B (en) 1997-03-21
GB9026998D0 (en) 1991-01-30
GB2251614B (en) 1994-12-14
FR2670487B1 (en) 1993-08-20
BE1005085A3 (en) 1993-04-13
CZ114093A3 (en) 1994-02-16
AP230A (en) 1993-01-27
DK0490689T3 (en) 1995-05-22
AU9072091A (en) 1992-07-08
WO1992010477A1 (en) 1992-06-25
JP2994037B2 (en) 1999-12-27
IS3790A7 (en) 1992-06-13
HK82697A (en) 1997-06-27
ES2069836T3 (en) 1995-05-16
EG20219A (en) 1997-11-30
ZA919750B (en) 1992-10-28
NL9102071A (en) 1992-07-01
ITRM910922A1 (en) 1993-06-11
PT99757A (en) 1992-12-31
NZ240942A (en) 1994-03-25
DE69108200T2 (en) 1995-07-20
IE62894B1 (en) 1995-03-08
CH684192A5 (en) 1994-07-29
ITRM910922A0 (en) 1991-12-11
CZ281931B6 (en) 1997-04-16
TW205035B (en) 1993-05-01
ATE119881T1 (en) 1995-04-15
IS1706B (en) 1998-12-10
IE914317A1 (en) 1992-06-17

Similar Documents

Publication Publication Date Title
CA2098302A1 (en) Medicaments
CA2105180A1 (en) Compositions containing sumatriptan
CA2274074A1 (en) Novel compounds with analgesic effect
MX9702380A (en) New carboxamides with antifungal activity.
CA2239174A1 (en) Novel compounds with analgesic effect
HUP0001170A3 (en) Pharmaceutical compositions containing benzimidazole-2-carbamate derivatives as active ingredients for the treatment of viral infections and cancer
CA2259621A1 (en) Isocoumarin derivatives and their use in medicines
CA2201477A1 (en) New pyrimidone derivatives with antifungal activity
CA2293823A1 (en) 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
HUP9603237A3 (en) Crystalline hydrochloride of (r)-(-)-2-{n-[4-(1,1-dioxydo-3-oxo-2,3-dihydro-benzisothiazo-2-yl)-butyl]-amino-methyl}-chromane, process for the preparation thereof and pharmaceutical compositions containing them
ES8506616A1 (en) N-aryl-alpha-amino-carboxamides.
AU3850600A (en) Dalda analogs and their use
HUP0000960A3 (en) Spray-dried paroxetine hydrochloride, process for it's preparation,use of the compound and pharmaceutical compositions containing the same
CA2301706A1 (en) Use of phanquinone for the treatment of alzheimer's disease
IL126022A (en) Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol in the preparation of pharmaceutical composition for treating depressive disorders and bipolar disorders
CA2278057A1 (en) Tachykinin antagonists
NZ303993A (en) Pharmaceutical compositions containing aminotetralin derivatives for treating cardiac disorders
MXPA02011533A (en) NOVEL FORMULATIONS OF agr; 2, 4 DISULFOPHENYL N TERT BUTYLNITRONE.
WO2001005386A3 (en) Pharmaceutical composition useful for the treatment of tinnitus and hearing loss
CA2100720A1 (en) Medicinal composition comprising tcf-ii
CA2388830A1 (en) Oral solution containing galanthamine and a sweetening agent
HRP940315A2 (en) Process for the preparation of pharmaceutical compositions containinbg active ingredient
IL130831A (en) Imino-aza-anthrayclinone derivatives, process for their preparation and pharmaceutical compositions comprising them for the treatment of amyloidosis
HUP9800277A3 (en) N-(1,2,3,4-tetrahydro-naphthyl- and -quinolyl)sulfonamide derivatives, their use for preparation of pharmaceutical compositions and pharmaceutical compositions containing them
UA41326C2 (en) Pharmaceutical composition for prevention or treatment of viral diseases, means for prevention or treatment of viral diseases

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry